ROS activation of the NF-κB signaling pathway plays a crucial role in liver inflammation (51), and inhibition of NF-κB activation has been shown to reduce pro-inflammatory cytokine secretion (TNF-α and IL-6), thereby alleviating NAFLD (52). Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.